UXT (Ubiquitously Expressed Transcript), also known as ART-27 or STAP1. is a conserved protein implicated in transcriptional regulation and cellular stress responses. It was initially identified as a coactivator of the androgen receptor (AR), interacting with its N-terminal domain to enhance ligand-dependent transcriptional activity. UXT is ubiquitously expressed across tissues and localizes to both the cytoplasm and nucleus, though its nuclear accumulation often correlates with active transcription. Structurally, it lacks enzymatic domains but serves as a scaffold protein, forming complexes with diverse partners, including transcription factors (e.g., NF-κB, p53) and components of the prefoldin-like chaperone family. These interactions suggest roles in modulating transcriptional machinery, chromatin remodeling, and protein stability.
UXT antibodies are essential tools for studying its functional mechanisms and disease associations. Research highlights its dual roles: in cancer, UXT overexpression may promote AR signaling in prostate cancer progression, while in other contexts, it acts as a tumor suppressor by stabilizing p53. Antibodies targeting UXT enable detection of its expression patterns, post-translational modifications, and dynamic subcellular redistribution under stress (e.g., hypoxia, DNA damage). Commercial UXT antibodies are typically validated for applications like Western blotting, immunofluorescence, and co-immunoprecipitation. Ongoing studies explore UXT’s involvement in neurodegenerative diseases, immune regulation, and viral infection pathways, underscoring its broad biological relevance. However, challenges remain in elucidating its precise molecular interactions and context-dependent roles, driving demand for highly specific antibodies.